Anti-CEAM7/ CEACAM7/ CGM2 monoclonal antibody

Anti-CEAM7/ CEACAM7/ CGM2 antibody for FACS & in-vivo assay

Target products collectionGo to CEACAM7/CEACAM7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0249-Ab-1/ GM-Tg-hg-MP0249-Ab-2Anti-Human CEACAM7 monoclonal antibodyHuman
GM-Tg-rg-MP0249-Ab-1/ GM-Tg-rg-MP0249-Ab-2Anti-Rat CEACAM7 monoclonal antibodyRat
GM-Tg-mg-MP0249-Ab-1/ GM-Tg-mg-MP0249-Ab-2Anti-Mouse CEACAM7 monoclonal antibodyMouse
GM-Tg-cynog-MP0249-Ab-1/ GM-Tg-cynog-MP0249-Ab-2Anti-Cynomolgus/ Rhesus macaque CEACAM7 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0249-Ab-1/ GM-Tg-felg-MP0249-Ab-2Anti-Feline CEACAM7 monoclonal antibodyFeline
GM-Tg-cang-MP0249-Ab-1/ GM-Tg-cang-MP0249-Ab-2Anti-Canine CEACAM7 monoclonal antibodyCanine
GM-Tg-bovg-MP0249-Ab-1/ GM-Tg-bovg-MP0249-Ab-2Anti-Bovine CEACAM7 monoclonal antibodyBovine
GM-Tg-equg-MP0249-Ab-1/ GM-Tg-equg-MP0249-Ab-2Anti-Equine CEACAM7 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0249-Ab-1/ GM-Tg-hg-MP0249-Ab-2; GM-Tg-rg-MP0249-Ab-1/ GM-Tg-rg-MP0249-Ab-2;
GM-Tg-mg-MP0249-Ab-1/ GM-Tg-mg-MP0249-Ab-2; GM-Tg-cynog-MP0249-Ab-1/ GM-Tg-cynog-MP0249-Ab-2;
GM-Tg-felg-MP0249-Ab-1/ GM-Tg-felg-MP0249-Ab-2; GM-Tg-cang-MP0249-Ab-1/ GM-Tg-cang-MP0249-Ab-2;
GM-Tg-bovg-MP0249-Ab-1/ GM-Tg-bovg-MP0249-Ab-2; GM-Tg-equg-MP0249-Ab-1/ GM-Tg-equg-MP0249-Ab-2
Products NameAnti-CEACAM7 monoclonal antibody
Formatmab
Target NameCEACAM7
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CEACAM7 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CEAM7/ CEACAM7/ CGM2 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLP002341human CEACAM7 Lentivirus particle
    ORF Viral VectorpGMLP002341human CEACAM7 Lentivirus plasmid


    Target information

    Target IDGM-MP0249
    Target NameCEACAM7
    Gene ID1087,705572
    Gene Symbol and SynonymsCEACAM7,CGM2
    Uniprot AccessionQ14002
    Uniprot Entry NameCEAM7_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseCancer
    Gene EnsemblENSG00000007306
    Target ClassificationTumor-associated antigen (TAA)

    The target: CEACAM7, gene name: CEACAM7, also named as CGM2. This gene encodes a cell surface glycoprotein and member of the carcinoembryonic antigen (CEA) family of proteins. Expression of this gene may be downregulated in colon and rectal cancer. Additionally, lower expression levels of this gene may be predictive of rectal cancer recurrence. This gene is present in a CEA family gene cluster on chromosome 19. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.